CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-26 | ARMISTICE CAPITAL, LLC Director | Sale | −0 | 5,440,000 | ||
| 2020-06-26 | ARMISTICE CAPITAL, LLC Director | Option exercise · Warrants | −16,666,667 | 0 | ||
| 2020-06-26 | ARMISTICE CAPITAL, LLC Director | Option exercise · Warrants | −0 | 0 | ||
| 2020-06-15 | Floroiu Cezar Andrei Chief Executive Officer | Grant or award · Stock Option (right to buy) | +845,280 | 845,280 | ||
| 2020-06-15 | Floroiu Cezar Andrei Chief Executive Officer | Grant or award · Stock Option (right to buy) | +900,000 | 900,000 | ||
| 2020-06-08 | Yedid Robert A. Director | Grant or award · Stock Option (right to buy) | +65,700 | 65,700 | ||
| 2020-06-08 | Finney Michael J. Director | Grant or award · Stock Option (right to buy) | +65,700 | 65,700 | ||
| 2020-06-08 | Davis Todd C Director | Grant or award · Stock Option (right to buy) | +65,700 | 65,700 | ||
| 2020-06-08 | Floroiu Cezar Andrei Director | Grant or award · Stock Option (right to buy) | +54,720 | 54,720 | ||
| 2020-06-08 | Echerd Margaret VP, Corporate Controller, PAO | Grant or award · Stock Option (right to buy) | +315,000 | 315,000 | ||
| 2020-06-08 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +360,000 | 360,000 | ||
| 2020-06-08 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +900,000 | 900,000 | ||
| 2020-06-03 | ARMISTICE CAPITAL, LLC Director | Sale | −400,000 | $2.77 | $1.1M | 7,000,000 |
| 2020-06-03 | ARMISTICE CAPITAL, LLC Director | Sale | −0 | 7,000,000 | ||
| 2020-06-02 | ARMISTICE CAPITAL, LLC Director | Sale | −800,000 | $2.75 | $2.2M | 7,400,000 |
| 2020-06-02 | ARMISTICE CAPITAL, LLC Director | Sale | −0 | 7,400,000 | ||
| 2020-06-01 | ARMISTICE CAPITAL, LLC Director | Sale | −200,000 | $2.74 | $548K | 8,200,000 |
| 2020-06-01 | ARMISTICE CAPITAL, LLC Director | Sale | −0 | 8,200,000 | ||
| 2020-05-27 | ARMISTICE CAPITAL, LLC Director | Sale | −200,000 | $2.61 | $522K | 8,400,000 |
| 2020-05-27 | ARMISTICE CAPITAL, LLC Director | Sale | −0 | 8,400,000 |
Page 15 of 23 · 442 trades